1-CBZ-4-哌啶甲酰肼 | 161609-80-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-CBZ-4-哌啶甲酰肼
• 中文别名: N-CBZ-4-哌啶甲酰肼；4-肼基羰基哌啶-1-羧酸苄酯
• 英文名称: benzyl 4-(hydrazinylcarbonyl)piperidine-1-carboxylate
• 英文别名: benzyl 4-(hydrazinocarbonyl)piperidine-1-carboxylate；1-benzyloxycarbonyl-4-piperidinecarbohydrazide；Benzyl 4-(hydrazinecarbonyl)piperidine-1-carboxylate
• CAS: 161609-80-9
• 化学式: C₁₄H₁₉N₃O₃
• mdl: MFCD06795951
• 分子量: 277.323
• InChiKey: DHNZPTXPFMSBML-UHFFFAOYSA-N

物化性质

• 沸点：
  498.3±44.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  84.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-CBZ-4-哌啶甲酰肼 在 palladium 10% on activated carbon 、 氢气 、 三氟乙酸 作用下， 以 甲醇 为溶剂， 反应 12.0h， 生成 4-(1,3,4-噁二唑-2-基)哌啶
  参考文献：
  名称：

  [EN] BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS
  [FR] COMPOSÉS AZA BICYCLIQUES EN TANT QU'AGONISTES DU RÉCEPTEUR MUSCARINIQUE M1.

  摘要：

  公开号：

  WO2015118342A8
• 作为产物：
  描述：

  1-Cbz-4-哌啶甲酸甲酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 以92 %的产率得到1-CBZ-4-哌啶甲酰肼
  参考文献：
  名称：

  [EN] SUBSTITUTED PIPERIDINES AND SUBSTITUTED TETRAHYDROPYRIDINES AS IMMUNE-MODULATING COMPOUNDS
  [FR] PIPÉRIDINES SUBSTITUÉES ET TÉTRAHYDROPYRIDINES SUBSTITUÉES EN TANT QUE COMPOSÉS DE MODULATION IMMUNITAIRE

  摘要：

  Described herein are compounds that are glutaminyl-peptide cyclotransferase like (QPCTL) protein modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of QPCTL activity.

  公开号：

  WO2023205173A1

文献信息

• [EN] AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS<br/>[FR] DÉRIVÉS D'AZOLE EN TANT QU'INHIBITEURS DE LA VOIE WNT
  申请人：OSLO UNIVERSITY HOSPITAL HF

  公开号：WO2010139966A1

  公开（公告）日：2010-12-09

  The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.

  本发明涉及公式I的新化合物，涉及其制备过程，含有这种化合物的药物配方以及它们在治疗中的应用。这些化合物在治疗和/或预防受到Wnt信号通路过度激活影响的疾病或病症中发挥特定作用。例如，它们可用于预防和/或延缓肿瘤细胞的增殖，例如结肠癌等癌症。
• Proline derivatives and use thereof as drugs
  申请人：Kitajima Hiroshi

  公开号：US20050245538A1

  公开（公告）日：2005-11-03

  The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the γ-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

  本发明旨在提供具有治疗效果的化合物，其作用是通过DPP-IV的抑制作用，并且作为药物产品具有令人满意的效果。本发明人发现，在丙氨酸的γ位上引入取代基的衍生物具有强效的DPP-IV抑制活性，并通过增加稳定性完成了本发明。
• Proline derivatives and the use thereof as drugs
  申请人：——

  公开号：US20040106655A1

  公开（公告）日：2004-06-03

  The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the &ggr;-position of proline represented by the formula (I) 1 wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

  本发明旨在提供具有治疗作用的化合物，由于DPP-IV抑制作用而具有满意的药物产品。本发明人发现，具有引入取代基的脯氨酸γ-位置的衍生物，其化学式为(I)1，其中每个符号如规范中所定义，具有强效的DPP-IV抑制活性，并通过增加稳定性完成了本发明。
• Tetrahydropyran derivatives and their use as therapeutic agents
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US06458830B1

  公开（公告）日：2002-10-01

  The present invention relates to compounds of the formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis and postherpetic neuralgia.

  本发明涉及式(I)的化合物，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，R10和n在此定义。该化合物特别适用于治疗或预防抑郁症，焦虑症，疼痛，炎症，偏头痛，呕吐和带状疱疹后神经痛。
• Azole Derivatives as WTN Pathway Inhibitors
  申请人：Holsworth Daniel

  公开号：US20120208828A1

  公开（公告）日：2012-08-16

  The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.

  本发明涉及公式I的新化合物，其制备过程，含有这些化合物的制药配方以及它们在治疗中的应用。这些化合物在防治或治疗Wnt通路信号过度激活引起的疾病或症状方面具有特殊用途。例如，它们可以用于预防和/或延缓肿瘤细胞的增殖，例如结肠癌等癌症的治疗。